Trial | NCT01751321  Report issue

Official Title

Glucose Variability With DPP-4 Inhibition

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    sitagliptin ...

  • Study Participants

    50
Glucose Variability With DPP-4 Inhibition
Patients with Type 2 Diabetes, age 35-75y., will be included in this double blind randomized placebo controlled study.

The sample size of 50 patients completing the 30 day study period is based on statistical input from Merck Research Laboratories, Rahway NJ.
Study Started
May 31
2013
Primary Completion
Sep 30
2013
Anticipated
Study Completion
Oct 31
2013
Anticipated
Last Update
Dec 17
2012
Estimate

Drug Sitagliptin, placebo

sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day

  • Other names: Januvia

sitagliptin, metformin, placebo Other

group- 25 patients will take sitagliptin 50 mg and metformin 1000 mg twice in a day group- 25 patients will take placebo 50 mg and metformin 1000 mg twice in a day

Criteria 

Inclusion Criteria:

Type 2 diabetes
receiving a stable dose of metformin ≥ 1500 mg
HbA1c 7,5% -10/0 %

Exclusion Criteria:

Type 1 diabetes
HbA1c < 7,5% and > 10,0%
No Results Posted